2 min read

OCT East Recap: RWD Trends in Clinical Studies

Research stakeholders met at this industry event to discuss trends in the clinical trial landscape.
This prominent clinical trial event discussed the future of real-world evidence and it's importance.

Pharmaceutical leaders and scientists converged at the recent Outsourcing in Clinical Trials East Conference in King of Prussia, Pennsylvania, to share ideas and discuss recent trends in the clinical trial landscape. One prominent topic continues to revolve around Real World Evidence and the trends emerging within RWE and RWD.

UBC’s Aaron Berger, Senior Director Safety Epidemiology Registries and Risk Management, presented on the essential role that Real World Data and Evidence can play in clinical trial design and execution. This presentation addressed several key concepts:

  • Regulator and payer communities have recognized the immense potential RWD brings to accelerating our ability to answer important questions about the safety and effectiveness of medical treatments.
  • Leveraging RWD is an essential consideration in the design and execution of clinical trials and registries.
  • There are practical applications and use cases for RWD in the domains of study design optimization, site and patient identification, and EMR/EDC interoperability.

UBC is a leading provider of evidence-generation capabilities and our unique expertise in “identifying the right evidence for the right purpose” sets us apart. Our expertise in evidence-generation supports the optimization of your approval pathway, product positioning, and safety profile maturation. By staying on top of RWE and RWD trends we are able to utilize fit-for-purpose technology that drives deep insight for sponsors.

To learn more about our practical applications of RWE and partnering in navigating the evidence-generation landscape, please contact us at contact@ubc.com to initiate the discussion on unlocking the value of RWD and RWE for your next clinical trial or registry.

Other Recent Posts

Press
4 min read

UBC Named a Pharmacovigilance Leader in Everest Group PV Operations PEAK Matrix Assessment 2025

UBC has been recognized by Everest Group as a leader in its 2025 Pre-approval Pharmacovigilance (PV) PEAK Matrix®, and a major contender in the Post-approval category. The recognition highlights UBC’s strength in delivering innovative, compliant, and patient-focused PV solutions across the drug development lifecycle.
Press
5 min read

UBC Announces Partnership with Osmind to Advance the Future of Mental Health Treatment and Research within REMS

First-of-its-kind partnership in mental health care reduces REMS implementation burden, improves the quality of REMS data, and optimizes safe medication use and health outcomes
Press
5 min read

UBC and Thread Expand SitePlus Offering and Active Studies with BioPharma Sponsors to Optimize Evidence Generation

This augments the central site model with additional research services and tech to widen recruitment and improves site and patient experience.